Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QCCTW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
KM501
|
|||||
| Synonyms |
KM 501; KM-501; KM501; Recombinant anti-HER2 domain II and domain IV bispecific antibody-MMAE conjugate (Xuanzhu); XZP-KM501
Click to Show/Hide
|
|||||
| Organization |
Xuanzhu Biopharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
| Puchem SID | ||||||
